BioNTech (NASDAQ:BNTX) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

BioNTech (NASDAQ:BNTX) had its price objective raised by analysts at Canaccord Genuity Group from $171.00 to $171.44 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 42.01% from the stock’s current price.

Other research analysts have also issued research reports about the company. Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Deutsche Bank Aktiengesellschaft lifted their price target on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, September 19th. TD Cowen cut their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. UBS Group lifted their target price on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Finally, HSBC boosted their price objective on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $138.67.

BioNTech Stock Performance

Shares of BioNTech stock opened at $120.72 on Wednesday. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The firm has a market capitalization of $28.94 billion, a P/E ratio of -57.49 and a beta of 0.26. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $113.52 and a two-hundred day simple moving average of $98.35.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.73 earnings per share. On average, equities analysts forecast that BioNTech will post -3.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after acquiring an additional 238 shares during the period. EverSource Wealth Advisors LLC boosted its stake in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares during the period. Planning Capital Management Corp grew its holdings in BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after buying an additional 450 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its position in shares of BioNTech by 430.3% during the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after acquiring an additional 1,562 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.